Tirzepatide Reduces Diabetic Eye Complications 36-69% vs GLP-1 Drugs Including NAION | Research

The takeaway

Tirzepatide was associated with 40% lower DR (HR 0.60), 37% lower DME (HR 0.63), 64% lower VH/RD (HR 0.36), 69% lower NAION (HR 0.31), and 56% lower vision-saving intervention need vs non-GIP GLP-1 RAs.

69% less NAION
While semaglutide raised NAION concerns, tirzepatide showed 69% LOWER NAION risk vs GLP-1-only drugs — a remarkable reversal

What the researchers found

Tirzepatide vs non-GIP GLP-1 RA (102,590 per cohort): DR HR 0.60 (0.54-0.65); DME HR 0.63 (0.52-0.74); VH/RD HR 0.36 (0.23-0.55); vision-saving interventions HR 0.44 (0.32-0.60); NAION HR 0.31 (0.15-0.64).

Why it matters

This is the first large study showing tirzepatide's broad ocular protective effects — and notably shows it REDUCES NAION risk rather than increasing it.

How the study worked

Nationwide retrospective cohort (June 2022-June 2025), 102,590 matched pairs, tirzepatide vs non-GIP GLP-1 RA, propensity-score matched for demographics/comorbidities/medications/ophthalmic encounters, 36-month follow-up.

What this study cannot tell us

Retrospective observational. Short tirzepatide market exposure. Cannot determine if GIP agonism drives the protection. Active comparator design means relative, not absolute, risk.

How to read the evidence

Very large propensity-matched cohort with multiple consistent subanalyses. Important evidence but observational.

When this study was published

Published in 2025.

The bigger picture

If confirmed, tirzepatide could be the first drug shown to comprehensively protect against diabetic eye disease AND the rare optic nerve condition NAION — reversing earlier safety concerns about GLP-1 drugs.

Questions still open

Does GIP receptor activation directly protect retinal and optic nerve cells?
How does tirzepatide's NAION-protective effect reconcile with semaglutide NAION risk?
Should ophthalmologists specifically recommend tirzepatide for diabetic eye disease?

Common questions

Does tirzepatide protect diabetic patients' eyes?

Dramatically. This study of 205,000 patients found tirzepatide reduced diabetic eye disease by 36-69% compared to other GLP-1 drugs, including a 69% reduction in a rare optic nerve condition (NAION).

What about the NAION concern with semaglutide?

Interestingly, while semaglutide has been linked to INCREASED NAION risk, tirzepatide showed the opposite — 69% LOWER risk. The GIP receptor activity unique to tirzepatide may explain this protective effect.

Read the original research

Ocular Outcomes with Tirzepatide Versus Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes.

Ophthalmology. Retina

View on PubMed ↗Publisher’s paper ↗

Citation

Hong, Alexander T; Lin, Forest; Keenan, Jeremy D; Stewart, Jay M. (2026). Ocular Outcomes with Tirzepatide Versus Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes.. Ophthalmology. Retina. https://doi.org/10.1016/j.oret.2026.02.002